Thousand Oaks, CA, United States of America

Hui-Ling Wang

USPTO Granted Patents = 26 

 

Average Co-Inventor Count = 10.8

ph-index = 9

Forward Citations = 224(Granted Patents)


Company Filing History:


Years Active: 2004-2025

where 'Filed Patents' based on already Granted Patents

26 patents (USPTO):

Title: Innovations by Hui-Ling Wang: A Pioneer in Cancer Treatment

Introduction

Hui-Ling Wang, based in Thousand Oaks, CA, is an accomplished inventor with an impressive portfolio of 25 patents. His work primarily focuses on developing innovative therapies targeting KRAS G12C, which is significant in treating several types of cancer. His contributions to the field exemplify the impact of innovative research and its potential to transform cancer treatment.

Latest Patents

Among his latest inventions are patents for "Substituted piperazines as KRAS G12C inhibitors," which detail compositions and methods for utilizing these inhibitors. These innovations are designed to treat disorders such as pancreatic, colorectal, and lung cancers. Another notable patent titled "Inhibitors of KRAS G12C and methods of using the same" further explores the applications of these inhibitors, solidifying Wang's role in advancing cancer therapeutics.

Career Highlights

Hui-Ling Wang is associated with Amgen Inc., where he applies his expertise to drive innovation in biopharmaceutical development. His relentless pursuit of new discoveries in the realm of cancer treatment has positioned him as a leading figure in his field. With 25 patents to his name, he continues to push the boundaries of medical science, emphasizing the importance of targeted therapies.

Collaborations

Throughout his career, Wang has collaborated with renowned professionals, including coworkers Ning Chen and Mark Henry Norman. These partnerships enhance the collaborative spirit needed in research and development, facilitating the effective translation of scientific findings into viable medical solutions.

Conclusion

Hui-Ling Wang's work exemplifies the intersection of innovation and invention in the realm of healthcare. His patents for KRAS G12C inhibitors reflect a commitment to addressing the urgent needs of cancer patients. Through his position at Amgen Inc., and his collaborations with talented colleagues, Wang continues to make strides in advancing cancer treatment and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…